Abstract
Tumor mutation burden (TMB) predicts response to immunotherapy in non-small cell lung cancer (NSCLC). The current TMB evaluation is expensive and not ......
小提示：本篇文献需要登录阅读全文，点击跳转登录
Full Text Link
